Crohn's disease and primary sclerosing cholangitis: a case report and review of the literature.
The comorbidity of Crohn's disease (CD) and primary sclerosing cholangitis (PSC) is uncommon. Diagnosing such patients can be difficult, as illustrated by the following case. The combination of CD and PSC should be considered in patients with CD who have abnormal liver function. Because patients with PSC often present asymptomatically, all patients with CD should be screened for PSC by checking serum liver tests. Review of the literature suggests that there is an increased potential in these patients for the development of malignancy and long-term prognosis is poor. We conclude that patients diagnosed with a combination of CD and PSC should be managed with periodic colonoscopy, CA 19-9 investigation, early liver and bowel imaging, and liver biopsy. The treatment of CD associated with PSC remains unsatisfactory and the possibility of liver transplantation should be considered.
Department of Gastroenterology, Hainan Provincial People's Hospital, China.
Xin-Pu
XP
Miao
Xiao-Ning
XN
Sun
Hong
H
Wei
Qin
Q
Ouyang
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018395:CA-19-9 Antigen / Q000097:blood; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D002760:Cholangiopancreatography, Endoscopic Retrograde; D015209:Cholangitis, Sclerosing / Q000175:diagnosis / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D003113:Colonoscopy; D015897:Comorbidity; D003424:Crohn Disease / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D008099:Liver / Q000473:pathology; D008111:Liver Function Tests; D016031:Liver Transplantation; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use; D011379:Prognosis; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018395:CA-19-9 Antigen; D002756:Cholagogues and Choleretics; D019804:Mesalamine; D014580:Ursodeoxycholic Acid